Companies › AnaptysBio
1 active drug program in 2 registered trials: 2 Phase 2; Immunology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Rosnilimab PD-1 agonist antibody | PDCD1 | Phase 2 | Rheumatoid Arthritis; Ulcerative Colitis | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06041269 | Rosnilimab | Phase 2 | Rheumatoid Arthritis | Immunology | Nov 2024 |
| NCT06127043 | Rosnilimab | Phase 2 | Ulcerative Colitis | Immunology | Jan 2026 |
Cash and short-term investments of $286m on 2026-03-31; operating cash outflow about $106m a year; runway about 32 months at that burn, to Dec 2028
Press releases filed as 8-K in the last year:
Held by 6 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Q32 Bio RAPT Therapeutics, Inc., a member of the GSK plc group of companies Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) Chengdu Kangnuoxing Biopharma Zura Bio
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.